BCIQ Profiles

Company Profile ReportTarget Profile Report
0909 iECURE ECP EMBARGO 7AM ET THURS
BioCentury & Getty Images

Emerging Company Profile

Wilson ventures into gene editing with iECURE launch, backed by $50M series A

Emerging Company Profile: OrbiMed, Versant back Jim Wilson’s latest launch, which applies gene editing to rare pediatric diseases

OrbiMed, Versant back Jim Wilson’s latest launch, which applies gene editing to rare pediatric diseases where standard gene replacement isn’t enough.

Sep 9, 2021 | 11:01 AM GMT

Gene therapy pioneer James Wilson is expanding his entrepreneurial vision into gene editing with the launch of iECURE, a company tackling the challenging gene editing application of in vivo gene insertion. 

iECURE launched on Thursday with a $50 million series A round led by OrbiMed Advisors and Versant Ventures, plus collaborations with the University

Read the full 1211 word article

How to gain access

Continue reading with a
two-week free trial.